Background: The aim of this study was to increase disease-free survival (DFS) in AML in CR1 using a high-dose cytarabine consolidation plus G-CSF as in vivo purging and mobilization of CD34+ cells before ablative therapy and peripheral blood autograft.
Introduction
Cytarabine has been combined with an anthracycline in the standard induction combination 7 + 3 for acute myeloid leukemia (AML) for more than two decades. Improvement in complete remission (CR) rates is more closely related to better supportive measures during the period of aplasia than to the extension of time or increase in dosage of cytarabine exceeding 100 mg/m 2 for seven days, or the incorporation of new anthracyclines [1] [2] [3] . Nor has the addition of a third drug during induction improved the rate of CR [4] . High-dose cytarabine during induction [3, 4] or intensification [3, 5] improves the duration of CR and increases disease-free survival (DFS), especially in younger patients. Allogeneic bone marrow transplantation in patients with an HLA-identical sibling has also been used with the purpose of increasing the rate of cure [6] [7] [8] [9] . In those patients without compatible donors, autologous bone marrow transplantation has become an alternative as post-remission therapy [7, 8, 11] .
In the present decade, peripheral blood progenitor cells have been widely used as a source of hematopoietic stem cells, and a shorter period of neutropenia, fewer hospitalization days and fewer treatment-related deaths (TRD) have resulted [10] [11] [12] . The concept of in vitro purging with maphosfamide or 4HC has also been used, with the objective of reducing the number of neoplasic cells infused [13, 14] . However, the hematological recovery was lengthened, and the resultant reduction in relapse rate remains controversial. More recently, high-dose cytarabine has been used as an in vivo purging with bone marrow harvested at the point of recovery of aplasia with a DFS similar to that reported with allogeneic transplantation [15] .
In November 1991, we started a treatment program for AML patients in first CR employing high-dose cytarabine followed by G-CSF for consolidation and mobilization followed by ablative therapy and autologous peripheral blood progenitor cell rescue. We describe the results of this strategy in a single-center study of 56 consecutive patients with 'intent to treat' criteria from consolidation onward.
Patients and methods

Patients
Of 56 patients with AML in 1CR who received consolidation at our institution from November 1991 to December 1996, 54 received autol- 34 20 ogous peripheral blood progenitor cell transplantations (APBT). Complete remission was defined by bone marrow showing less than 5% blast infiltration (Ml) and by peripheral blood counts with more than 1.0 x 10 9 /l neutrophils, more than 100 x 10 9 /l platelets and a hematocrit of more than 30%. Five patients with pre-existing myelodysplasic features at diagnosis were included. Patients with other secondary leukemias were excluded. The demographic data and disease characteristics are listed in Table 1 . Thirteen patients, mainly those who started treatment at other institutions, did not have cytogenetic evaluations at diagnosis. In five patients, metaphases were not found, and in 38 patients, a cytogenetic study was done. Cytogenetic data was classified as indicating favorable prognosis if either t(8;21). t(15;17) or an abnormality of chromosome 16 was present. Normal karyotype was classified as intermediate prognosis. Unfavorable cytogenetic prognosis was designated if multiple numerical and/or structural abnormalities, trisomy 8, monosomy 5 or 7 or complex chromosome 17 abnormalities were observed. Five patients (9%) experienced delays longer than six months between diagnosis and transplant (the median was five months). Fortythree of the patients included in this study were treated at our institution from diagnosis onward (less than 70 years of age, obtaining complete remission and receiving consolidation and mobilization treatment) and 13 were referred to us from other centers for consolidation, mobilization and autograft. Only two patients who completed consolidation and mobilization (both from our center) did not proceed to autograft. In one case this was due to a lack of CD34+ cells in the leukopheresis product (this patient remains disease-free four months post-consolidation), and the other was a patient who had an acceptable leukopheresis product, but developed a fungal lung infection {Acremonium spp.) for which high doses of amphotericin were necessary, precluding the possibility of subsequent autograft (this patient remains in CR 23 months post-consolidation). These two patients were No patient died during consolidation, and none had a relapse before transplant. The evaluation for this study was done in July 1997.
Treatment
The protocol used for all of the adult patients (> 15 years old) is described in Table 2 . Patients not in CR after one course of induction treatment received a second course. Patients who did not enter CR after the second course of treatment were withdrawn from the study. The 11 pediatric patients (^ 15 years) entered in this study were treated with a BFM-like protocol [16], also described in Table 2 . Beginning in November 1991, both protocols included the option of an ablative regimen and autograft following high-dose ara-C consolidation. The autograft option was the accepted policy at our institution for patients younger than 70 years of age. G-CSF (Filgrastim) 5 ug/kg SC was administered daily to all patients as mobilization, beginning 24 hours after the completion of consolidation and continued until the completion of stem cell leukapheresis. The protocols used were approved by the Institutional Review Board of the 'Angelica Ocampo' Hospitalization and Clinical Research Center and all the patients gave oral informed consent according to Argentine regulations for all phases of the study.
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Statistical analysis
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Results
The median length of follow-up was 18 months, with a range of 1-68 months for all patients and 32.5 months (range 6-68) for those who are alive without relapse.
Hematopoietic recovery and support
Fifty-one of the 54 transplanted patients reached neutrophil recovery of ^ 1.0 x 10 9 /l and were evaluable (three had TRD before recovery) and 44 of the 54 patients reached platelet recovery of ^25 x 10 9 /l and were evaluable (five had TRD before recovery and five relapsed and died before recovery). The median time to neutrophil recovery was 13 days, and to platelet recovery 32 days (Table 3) . Of those who achieved platelet recovery to ^25 x 10 9 /l, 11 never reached a platelet count of 100 x 10 9 /l (one was due to TRD, six because of relapse, while four are in an early stage of CR period).
In a previous study by our group we showed by multiregression analysis that the diagnosis of AML was associated with delayed recovery of neutrophils and platelets [10] .
Disease-free survival
Of the 56 eligible patients, 16 relapsed and six died due to transplant complications. At 30 months 61% of the patients remain disease-free. Twelve of the relapses oc- curred within the first year after transplant, at a median of five months. Two patients, both of whom were in the unfavorable cytogenetic group at diagnosis, had late relapses, at 36 and 45 months. Of the 16 who relapsed, 15 died and one is alive and in second CR, six months after an allogeneic transplant from an HLA-identical sibling donor (Figure 1 ). Of the 56 eligible patients, 31 were younger than 36 years old and 23 of these are disease-free, their DFS being 76% at 30 months. One 12-year-old patient relapsed at 36 months. Twenty-five patients were older than 35 years and their DFS at 30 months was 43%. Another patient, 55 years old, had a late relapse at 45 months. The difference in DFS according to age was statistically significant (P = 0.0215, Figure 2 ).
Overall survival
Twenty-one of the 56 eligible patients died, six due to TRD and 15 after relapse of leukemia and progression.
At 30 months, 62% of them remain alive. The two late deaths, at 38 and 46 months, were of those patients who had late relapses (Figure 3 ). The overall survival at 30 months for the 31 patients less than 35 years old was 78%, compared to 43% for the patients older than 35 years. In these two age groups, seven and 14 patients died, respectively, with one late death in each group (P -0.0137, Figure 4) .
No statistical difference in event-free survival was observed according to cytogenetic prognostic groups; the two late relapses and deaths, however, belong to the unfavorable cytogenetic group.
Toxicity
Of the 54 transplanted patients, six (11%) had TRD, two of sepsis, two of CM V infection, one of fungal infection and one of CNS bleeding, all less than 72 days after infusion. Other severe non-infectious complications observed during ABMT are listed in Table 5 . The patient with veno-occlusive disease is alive at 68 months after 100 n 
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Infectious complications
The median number of days with fever for the 54 transplanted patients was 3 (range 0-21, Table 4 ) and in most of them the infections were resolved with the first empiric antibiotic regimen (cefoperaxone or ticarcillin/ clavulanate plus gentamicin). Three patients (5.5%) did Infections by CMV developed in four patients (7.4%); three had pneumonia (5.5%) and one had fever with high-grade antigenemia. The deaths of five patients were related to the infection, two to sepsis by methicillin-resistant Staphylococcus aureus, two to CMV pneumonia and one to fungal infection due to Acremonium spp. In all instances, death occurred despite appropriate antimicrobial treatment.
Discussion
In this study 54 patients with AML in first CR received an autograft of peripheral blood progentior cells purged in vivo with an intensification of high-dose cytarabine plus G-CSF. In these patients the TRD was 11%. At 30 months, the probability for all 56 eligible patients of remaining disease-free was 61%, and alive, 62%. Disease-free survival of less than 25% at 30 months has been observed for AML patients treated with a 7 + 3 induction regimen and standard dose consolidation including cytarabine and/or maintenance [1] [2] [3] [4] . High-dose cytarabine has been compared with standard-dose cytarabine during induction and/or consolidation in several randomized studies [3] [4] [5] . No difference has been observed between the CR rates, with higher toxicity in high-dose groups [3, 4] . However, in the SWOG study [3] the duration of CR was better following high-dose cytarabine during induction and/or consolidation; 33% vs. 21% at four years for those aged less than 50, and 21% vs. 9% for those aged 50-64. The Australian Leukemia Study Group [4] , employing high-dose cytarabine during induction and intensification versus standard doses, both in combination with daunorubicin and etoposide, had DFS rates at five years of 49% and 24% (P -0.0005). The CALGB [5] also did a randomized study with three different doses of cytarabine during intensification. The probability of remaining in CR after four years for patients younger than 61 years old was 24%, 29% and 44% for respective doses of 100 mg/m 2 , 400 mg/m 2 and 3 g/m 2 , (P = 0.002). Thus, high-dose cytar-abine has become the standard intensification strategy to compare with allogeneic and autologous transplantation. The International Bone Marrow Transplant Registry [6] has reported TRD of 21% ± 2% in 805 patients with early leukemia and HLA-identical sibling transplant. The three-year DFS was 66%. The same group of patients transplanted with mis-matched unrelated donors had a TRD of 69% ± 8% and three-year DFS of 26%±7%CP<0.001).
Several studies have compared the outcome in first CR with high-dose cytarabine vs allogeneic vs autologous transplant with controversial results. Sierra et al. [8] from Spain report their results with 63% ± 7% fouryear DFS for autologous transplant (47 pts) compared to 38% ± 11% for allogeneic transplant (26 pts, P -0.02). Reiffers et al. [11] , in a French Cooperative Study in AML in first CR, obtained a DFS at three years of 66.5% ± 16% (36 pts ^45 years old) with allogeneic transplant, 52% with autologous transplant (33 pts) and 42% for those treated with chemotherapy (38 pts). The difference between allogeneic transplant and chemotherapy was significant (P -0.02), but no statistical difference was found between autologous transplant and either allogeneic transplant or chemotherapy.
The European Cooperative Group for Blood and Marrow Transplantation [21] has compared autologous vs allogeneic bone marrow transplant. The DFS at four years was 55% ± 3% for allograft (516 pts) and 42% ± 3% for autograft (598 pts) (P = 0.003), with TRD of 27% ± 2% and 13% ± 2%, respectively.
Zittoun et al. [22] , in a large European study, compared 95 autologous vs. 144 allogeneic bone marrow transplantations vs. 104 intensive-chemotherapy patients. The projected rate of DFS at four years was 48% ± 5%, 55% ± 4% and 30% ± 4%, respectively (P = 0.05). However, the overall survival after CR was similar in the three groups.
Cassileth et al. [23] , of the ECOG intergroup report a comparison in AML in first CR of autologous transplant, allogeneic transplant and high-dose cytarabine. The authors conclude that no difference in DFS and overall survival was observed among the three postremission therapies.
With the purpose of reducing the neoplastic cell contamination in the hematopoietic product infused, several authors have employed different types of in vitro purges, such as drugs (mafosfamide, 4 HC), monoclonal antibodies or negative selection of CD34+ cells [14, 19, 22] . At present, no conclusive results have been obtained and most of the centers continue to use progenitor cells without purge.
Stein et al. [15] , report results of in vivo purging of autologous bone marrow using high-dose cytarabine prior to the harvest in AML in first CR, resulting in a 24-month DFS of 61%.
Peripheral blood has been increasingly used in recent years as a source of progenitor cells for autograft. This has been accompanied by a significant decrease of neutropenic days, thrombocytopenic days, fever, antibiotic use and hospitalization days [10, 12].
Reiffers et al. [12] , describe 1422 auto-transplant patients with AML in first CR as reported to the EBMT registry. The range of stem cells (blood versus unpurged bone marrow) had a significant influence on hematopoietic recovery but did not affect the DFS.
Schiller et al. [24] , recently published the results of a study similar to the present one, with a total of 59 consecutive patients with newly diagnosed AML in CR1 who were eligible for consolidation chemotherapy and autologous transplant. The peripheral blood progenitor cells were harvested after a single consolidation with high-dose cytarabine, mitoxantrone and r-Hu-G-CSF. Forty-six eligible patients received myeloablative chemoradiotherapy and autograft. Thirteen patients did not undergo transplant for different reasons. The three-year actuarial DFS for all eligible patients was 42% ± 14%, while for those patients receiving autologous transplant, it was 41% ± 16%.
In conclusion, these data indicate that a substantial proportion of patients with AML in CR1, particularly those less than 35 years of age, can benefit from a prolonged DFS with APBT performed after in vivo purge with high-dose cytarabine. This strategy appears to be just as effective as allogeneic and autologous 'purged' bone marrow transplantation, with faster hematopoietic recovery.
